Evoke Pharma receives notice of allowance for use of GIMOTI from USPTO

Evoke Pharma (EVOK) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office, or USPTO, for a U.S. patent application covering the use of GIMOTI in patients with moderate to severe symptoms of gastroparesis. The allowed application is a continuation of U.S. Patent No. 11,517,545, and further expands Evoke’s intellectual property estate around intranasal metoclopramide. Upon issuance, the patent will be expected to expire in December 2036 and the company intends to list the patent in the FDA’s Orange Book, extending market exclusivity for GIMOTI beyond other existing patents. Evoke Pharma has filed another U.S. continuation application to pursue additional claims directed to treatments for this patient population.